Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

AAN 2023: Rozanolixizumab yields benefits across gMG patient groups

People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced reductions in disease severity scores regardless of disease duration, prior treatments, and initial disease severity, new analyses suggest. Findings were presented by Tuan Vu, MD, of the University of South…

AAN 2023: Vyvgart for 2 years seen to ease symptoms of gMG in study

Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of generalized myasthenia gravis (gMG) among participants in an open-label extension study, according to an analysis of new data. “This analysis suggests that long-term efgartigimod [Vyvgart] treatment is well tolerated and…

AAN 2023: Zilucoplan eases symptoms in all subgroups in trial

Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients participating in the Phase 3 RAISE clinical trial. Trial data showed treatment effects were consistent, regardless of sex, age, disease duration, prior use of certain treatments, or thymoma status. Findings…

Robot-assisted thymectomy ‘safe and feasible’ in MG: Study

Robot-assisted surgery to remove the thymus is generally safe for people with myasthenia gravis (MG), with most patients who undergo the procedure seeing a reduction in symptom severity afterward, a study reports. “This retrospective follow-up study showed that robotic thymectomy [thymus removal surgery] is safe and feasible in patients…

Vyvgart approved as add-on in UK for adults with AChR-positive gMG

Vyvgart (efgartigimod) won approval in the U.K. as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR)-targeting antibodies. “We are pleased to announce this latest regulatory approval of Vyvgart, another exciting advancement toward our vision of making our…

Early, aggressive treatment better for controlling MG symptoms: Study

Early and aggressive treatments tend to lead to better control of myasthenia gravis (MG) symptoms, a recent study reports. The study suggests MG patients given early treatment with high doses of the corticosteroid methylprednisolone directly into the bloodstream are more likely to have minimal disease manifestations. “The data presented…